市場調査レポート

院内感染管理市場(殺菌・消毒・検査・治療)

The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)

発行 Kalorama Information 商品コード 278892
出版日 ページ情報 英文 230 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
院内感染管理市場(殺菌・消毒・検査・治療) The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)
出版日: 2013年08月09日 ページ情報: 英文 230 Pages
概要

院内感染・医療関連感染(HAI)のコストを考慮すると、医療産業における感染および感染関連コストの削減に役立つソリューションの需要は高まっています。米国の疾病対策センター(CDC)は入院患者のおよそ20人に1人または5%がHAIの病気にかかっていると推測しています。世界では、先進地域における入院患者の院内感染率は3.5%から12%となっています。このことは、これらの感染を検査・治療・予防する企業へ市場機会を生み出しています。

当レポートは、ヘルスケアを提供する現場で最も頻繁に広がる感染症のタイプである細菌性の院内感染を取り上げ、医療環境における感染症の防止、検査および治療に重点を置いて調査しており、主な市場機会、主要企業のプロファイルなどをまとめ、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

第2章 イントロダクション・産業動向

  • 概要
  • 病原体のイントロダクション
  • 世界の人口統計
  • 感染症の説明
  • 感染リスク評価:病院の部門別
  • 看護施設における国際的動向
  • 経済的動向
  • 医療費および実際の医療転帰の比較
  • 医療関連感染(HAI)を予防するための米国政府の国家的プラン
  • ケーススタディ
  • 感染症と薬剤耐性
  • 主な人口集団における薬剤耐性
  • 耐性を減らす方法
  • 入院患者のスクリーニング
  • 医薬品メーカー・マーケッターの動向

第3章 感染予防

  • 概要
  • 感染方法
  • リスクの高い設備・部署
  • 技術概要
  • 殺菌vs.消毒
  • 装置・ソリューション
  • 熱/蒸気殺菌
  • 化学薬品殺菌
  • 放射線殺菌
  • 市場概要
  • 院内感染予防市場:地域別
  • 競合分析

第4章 感染検査

  • 概要
  • 薬剤耐性/感受性検査
  • 特定の深刻な院内感染検査
  • 結核
  • 新しい開発動向
  • 市場概要
  • 総市場規模・予測
  • 院内感染検査市場:地域別
  • 競合分析

第5章 感染治療

  • 概要
  • 抗菌治療の原理
  • 感染微生物
  • 抗菌製品の分類
  • 治療ガイドライン
  • 主要製品

第6章 院内感染管理の市場機会

  • 市場の検討事項
  • 市場概要
  • 院内感染管理市場:地域別

第7章 企業プロファイル

  • イントロダクション
  • Advanced Sterilization Products
  • Becton, Dickinson
  • Belimed
  • bioMerieux
  • Cantel
  • Cepheid
  • Getinge Group
  • Kimberly-Clark
  • Merck & Co
  • Nordion
  • Pfizer
  • Roche
  • Sakura Seiki
  • Steris
  • Tso3

図表リスト

目次
Product Code: KLI5094606

Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions. This has created a market opportunity for companies that can test for, treat and help prevent these infections. This opportunity is detailed in Kalorama Information's report, The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment)

This report focuses on preventing, testing and treating infections in the healthcare environment. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the health care delivery setting, and b) the practical aspects of diagnosis and therapy are more meaningful based on a combination of medical and financial considerations.

The report will provide a market analysis for each of the three areas:

  • Prevention
  • Testing
  • Treatment

The infection control market is a stable one for companies involved in these areas. As long as there are infections there will always be a need for controlling these infections. It is a fact that diseases evolve and that new approaches to preventing, diagnosing and treating will be required for the long-term.

Market analysis in this report considers primarily the epidemiological considerations and the size patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis.

Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.

In looking at infections in the health environment, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for preventing, detecting and treating these infections. To some extent, we are limited by the activity of the industries associated with the activities mentioned above for these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.

The majority of competitive participation for Hospital-Acquired Infection control and is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America.

Companies included in this report are:

  • Advanced Sterilization Products
  • Becton Dickinson
  • Belimed AG
  • bioMerieux
  • Cantel
  • Cepheid
  • Getinge
  • Kimberly-Clark
  • Merck & Co.
  • Nordion
  • Pfizer
  • Roche
  • Sakura Seiki
  • Steris
  • TSO3

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Overview
  • The Nosocomial Infection
  • Scope and Methodology
  • Total Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

  • Overview
  • Introduction to Pathogens
  • Classification of Antibacterial Organisms
  • Patient Risk Factors
  • General Infection Statistics
  • Populations at Risk for Infection
  • Demographics of the World
  • Life Expectancy
  • Nosocomial Infection Statistics
  • Common Hospital (nosocomial) Infections
  • Description of Infections
  • Infection Risk Assessments by Hospital Department
  • Burn Units
  • Intensive Care Units
  • Emergency Departments
  • Hospital Length of Stay
  • Extended Stay Environments
  • International Trends in Nursing Facilities
  • Economic Trends
  • Comparison Between Healthcare Spending and Real Health Outcomes
  • U.S. Government's National Plan to Prevent Healthcare Associated Infections (HAIs)
  • Steering Committee
  • The American Recovery and Reinvestment Act of 2009
  • Affordable Care Act (ACA) Funding
  • Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Funding
  • U.S. Statewide Standardized Infection Ratio
  • Reduction in Hospital Acquired Infections
  • Reduction in Infections in Israel
  • Burden of Hospital Acquired Infections
  • Hospital-Acquired Infection Surveillance Process
  • Case Studies
  • Arizona Prevention Study
  • Connecticut Funding for HAI Prevention and Reporting
  • Pennsylvania Study of HAI Admissions and Readmissions
  • Infections and Drug Resistance
  • Easing Approvals of Antibiotics
  • Causes of Drug Resistance
  • Antibiotic Abuse
  • Antibiotic Use in Agriculture
  • Drug Resistance in Select Populations
  • Children
  • The Elderly
  • Compromised Individuals
  • Measures for Reducing Resistance
  • Testing for the Selection of Anti-bacterial Therapy
  • Monitoring Therapy
  • Screening Hospitalized patients
  • Pharmaceutical Manufacturer and Marketer Trends
  • Trends in Partnerships and Alliances
  • Developers Trends

CHAPTER THREE: INFECTION PREVENTION

  • Overview
  • Methods of Transmission
  • Airborne
  • Contact
  • Droplet
  • Vehicle
  • High-Risk Facilities or Departments
  • Technology Overview
  • Potential Use of Copper for Reducing Infections
  • Wide Area Disinfection Methods
  • Software for Infection Detection and Control
  • Antiseptic-Coated Catheters
  • Sterilization vs. Disinfection
  • Sterilization
  • Disinfection
  • Equipment and Solutions
  • Heat/Steam Sterilization
  • Developments
  • Chemical Sterilization
  • Sterilants
  • Developments
  • Radiation Sterilization
  • Developments
  • Market Overview
  • Hospital-Acquired Infection Prevention Market by Geographical Region
  • Competitive Analysis

CHAPTER FOUR: INFECTION TESTING

  • Overview
  • Drug-Resistance/Susceptibility Testing
  • Genotypic Methods
  • DNA Sequencing
  • Solid-phase Hybridization Techniques
  • Microarrays
  • Real-time Polymerase Chain Reaction Techniques
  • Phenotypic Methods
  • Phage-based Assays
  • Colorimetric Methods
  • The Nitrate Reductase Assay
  • Specific Serious Hospital-Acquired Infection Testing
  • Acinetobacter Baumannii
  • Clostridium Difficile
  • Developments
  • Hospital-Acquired Pneumonia
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Methicillin-resistant Staphylococcus Aureus (MRSA)
  • Vancomycin-Intermediate/Resistant Staphylococcus Aureus (VISA/VRSA)
  • Developments
  • Tuberculosis
  • Developments
  • Urinary Tract Infections
  • Vancomycin-resistant Enterococcus
  • Developments
  • Ventilator-Associated Pneumonia
  • New Developments
  • Market Overview
  • Total Market Size and Forecast
  • Hospital-Acquired Infection Testing Market by Geographical Region
  • Competitive Analysis

CHAPTER FIVE: INFECTION TREATMENT

  • Overview
  • Principles of Anti-bacterial Therapy
  • Infecting Organism
  • Antibiotic Sensitivity Testing
  • Site of Infection
  • Host Defenses and Organ Function
  • Antibiotic Pharmacokinetics
  • Monitoring Therapy
  • Classifications of Antibacterial Products
  • Carbapenems
  • Cephalosporins
  • Macrolides
  • Penicillins
  • Quinolones
  • Sulfonamides
  • Tetracyclines
  • Treatment Guidelines
  • Clostridium Difficile
  • Gastroenteritis
  • Hospital-Acquired Pneumonia
  • Ventilator-associated Pneumonia
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Stenotrophomonas maltophilia
  • Tuberculosis
  • Urinary Tract Infections
  • Leading Products
  • New Developments
  • Total Market Size and Forecast
  • Hospital-Acquired Infection Treatment Market by Geographical Region
  • Competitive Analysis

CHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL-ACQUIRED INFECTION CONTROL

  • Market Considerations
  • Market Overview
  • Hospital-Acquired Infection Control Market by Geographical Region

CHAPTER SEVEN: COMPANY PROFILES

  • Introduction
  • Advanced Sterilization Products
  • Company Performance
  • Becton, Dickinson
  • Company Performance
  • Belimed
  • Company Performance
  • bioMerieux
  • Company Performance
  • Cantel
  • Company Performance
  • Cepheid
  • Company Performance
  • Getinge Group
  • Company Performance
  • Kimberly-Clark
  • Company Performance
  • Merck & Co
  • Company Performance
  • Nordion
  • Company Performance
  • Pfizer
  • Company Performance
  • Roche
  • Company Performance
  • Sakura Seiki
  • Steris
  • Company Performance
  • Tso3
  • Company Performance

LIST OF MAJOR PROVIDERS

Back to Top